Compound Screening TRIZ Cases

A nuclease complementation assay turns target protein stabilization into a fluorescent readout for rapid, automated screening of drug compounds.

Restricting lipid or mineral intake in hairless animals induces meibomian gland plugging and telangiectasia for eyelid drug evaluation.

Blocking RAGE-tau oligomer binding reduces neuronal tau uptake and propagation, helping ameliorate cognitive and behavioral impairments.

By merging flow cytometry with microscopy, this case captures multi-channel single-cell images at high throughput without losing morphology.

A cell-based synthetic lethality assay screens compounds that kill PKD1/PKD2-deficient cyst cells while sparing healthy kidney tissue.

Non-activated cyanine and rhodamine compounds label intracellular proteins in dead cells without toxic nucleic acid staining or unstable amine reactivity.

LXR agonists raise ApoE and suppress metastasis promoters to slow melanoma spread and treat drug-resistant disease.

Open microwell perfusion tracks single effector-cell killing over time while preserving target-cell viability for cell therapy potency scoring.

Directly detect polymerase interference with optical tweezers to screen drug candidates faster and reveal binding dynamics early.

Ligand-gated split proteins stabilize ternary complexes to control target protein activity and localization with precise spatiotemporal regulation.

Targeting lysosomal ABCA1 reduces cholesterol buildup and SASP-driven inflammation in age-related osteoarthritis and sarcopenia.

Alternative HRS splice variants isolate WHEP and anticodon-binding domains to modulate cytokines, apoptosis, and angiogenesis.

Self-cleaving probe chemistry boosts signal over background after enzyme activation, enabling sensitive nitroreductase and hypoxia detection.

Controlled peanut flour formulations with characterized Ara h1, Ara h2, and Ara h6 support oral immunotherapy to reduce severe allergy risk.

Suppressing hSATII RNA and boosting CTCF enables selective killing of senescent and cancer cells while supporting early cancer detection.

Clostridium fractions or active substances induce colonic regulatory T cells and suppress effector T-cell proliferation for immune disease treatment.

Blocking CAF-secreted TSG-6 helps overcome stromal and myeloid suppression, improving immune checkpoint therapy in cold tumors.

Blocking SIRPα-CD47 drives MDSC differentiation into non-suppressive lymphoid cells, reducing immunodepression in cancer.

Selective PDE4B inhibition offers a targeted option for refractory epilepsy by reducing seizure frequency, severity, and neuronal hyperexcitability.

Non-infectious EVs with viral glycoproteins enable rapid, automated neutralizing antibody screening without handling live virus.

Olfactory receptor binding profiles replace subjective surveys to set odorant concentrations that appeal to adults or deter underage users.

Blocking CD47-SIRPα signaling with anti-CD47 antibodies restores phagocytosis of leukemia stem cells and tumor cells to counter immune evasion.

Automated plate movement and contact-type patch staining improve blood smear uniformity and accuracy without skilled manual handling.

A fusion protein assay screens compounds that block botulinum neurotoxin binding to SV2, enabling safer antitoxin evaluation and in vivo candidate discovery.

Receptor-dependent toxin fusions paired with CRISPR screens identify orphan receptor-ligand pairs without cloning or protein purification.

Distinct live-cell fluorescence separates target cells from stroma to quantify co-culture status for faster, standardized therapy-response screening.

Bioprinted 3D tumor models combine HLA-matched cell types and perfusable vasculature to better predict drug response and support personalized therapy.

Novel labeled peptide substrates enable precise calpain-5 activity assays and inhibitor screening for retinal disease therapy.

RTKN2, MAST4, FOXO1, and APP marker profiling improves Alzheimer's diagnosis and supports earlier intervention beyond amyloid-focused methods.

A screened set of human microRNAs drives adult cardiomyocyte proliferation to support cardiac regeneration after cell loss.

A 3D collagen tumor model screens Notch activators that drive MET in cancer stem cells, boost chemotherapy response, and spare normal stem cells.